Radiopharm Theranostics Ltd Logo

Radiopharm Theranostics Ltd

Developing first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer.

RADX | US

Overview

Corporate Details

ISIN(s):
US75041J1016
LEI:
Country:
United States of America
Address:
LEVEL 3, 62 LYGON STREET, 3053 CARLTON VIC
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Radiopharm Theranostics is a clinical-stage biotechnology company developing a portfolio of first-in-class radiopharmaceuticals for the diagnosis and treatment of cancer. The company is advancing a diverse pipeline based on proprietary platforms—including antibodies, nanobodies, peptides, and small molecules—to address significant unmet needs in oncology. Its strategy focuses on pioneering novel oncology targets, distinguishing itself from therapies aimed at more established pathways. Key differentiators include strategic collaborations, such as a joint venture with MD Anderson Cancer Center, and a focus on operational excellence and reliable isotope supply chains.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Radiopharm Theranostics Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Radiopharm Theranostics Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Radiopharm Theranostics Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Kiniksa Pharmaceuticals International, plc Logo
Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.
United States of America
KNSA
KIORA PHARMACEUTICALS INC Logo
Developing advanced small molecule therapies for vision-threatening retinal diseases.
United States of America
KPRX
KISSEI PHARMACEUTICAL CO.,LTD. Logo
Develops innovative drugs for urology, renal diseases, and rare or intractable diseases.
Japan
4547
Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden
KLAR
Klotho Neurosciences, Inc. Logo
Advancing gene and cell therapies for neurodegenerative disorders, cancer, and chronic diseases.
United States of America
KLTO
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan
9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan
4967
Kodiak Sciences Inc. Logo
Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.
United States of America
KOD
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan
177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea
102940

Talk to a Data Expert

Have a question? We'll get back to you promptly.